1. Lee JM, Turini M, Botteman MF, Stephens JM, Pashos CL. Economic burden of head and neck cancer: a literature review. Eur J Health Econ. 2004 Feb;5(1):70-80.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993 Jan;328(3):184-94.
4. Gregoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v184-6.
5. Bernstein JM, Bernstein CR, West CM, Homer JJ. Molecular and cellular processes underlying the hallmarks of head and neck cancer. Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2585-93.
6. Bose P, Brockton NT, Dort JC. Head and neck cancer: from anatomy to biology. Int J Cancer. 2013 Nov;133(9):2013-23.
8. Lampri ES, Chondrogiannis G, Ioachim E, Varouktsi A, Mitselou A, Galani A, et al. Biomarkers of head and neck cancer, tools or a gordian knot. Int J Clin Exp Med. 2015 Jul;8(7):10340-57.
9. Guerra EN, Acevedo AC, Leite AF, Gozal D, Chardin H, De Luca Canto G. Diagnostic capability of salivary biomarkers in the assessment of head and neck cancer: a systematic review and meta-analysis. Oral Oncol. 2015 Sep;51(9):805-18.
10. Juodzbalys G, Kasradze D, Cicciu M, Sudeikis A, Banys L, Galindo-Moreno P, et al. Modern molecular biomarkers of head and neck cancer. Part I. Epigenetic diagnostics and prognostics: systematic review. Cancer Biomark. 2016;17(4):487-502.
11. Guerra EN, Rego DF, Elias ST, Coletta RD, Mezzomo LA, Gozal D, et al. Diagnostic accuracy of serum biomarkers for head and neck cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016 May;101:93-118.
12. van Ginkel JH, Slieker FJ, de Bree R, van Es RJ, Van Cann EM, Willems SM. Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: a systematic review of the literature. Oral Oncol. 2017 Dec;75:8-15.
14. Pencik J, Wiebringhaus R, Susani M, Culig Z, Kenner L. IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer. Swiss Med Wkly. 2015 Dec;145:w14215.
16. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat. 2007 Apr;102(2):129-35.
18. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003 Sep;73(9):712-6.
19. Riedel F, Zaiss I, Herzog D, Gotte K, Naim R, Hormann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res. 2005 Jul-Aug;25(4):2761-5.
20. Andersson BA, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, Lofgren S, et al. Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2014 Mar;140(3):515-9.
21. Chang KP, Kao HK, Wu CC, Fang KH, Chang YL, Huang YC, et al. Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013 May;148(5):786-91.
22. Ren JG, Man QW, Zhang W, Li C, Xiong XP, Zhu JY, et al. Elevated level of circulating platelet-derived microparticles in oral cancer. J Dent Res. 2016 Jan;95(1):87-93.
23. Lotfi A, Shahidi N, Bayazian G, AbdollahiFakhim S, Estakhri R, Esfahani A, et al. Serum level of interleukin-6 in patients with oral tongue squamous cell carcinoma. Iran J Otorhinolaryngol. 2015 May;27(80):207-11.
24. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):929-35.
26. Sotirovic J, Peric A, Vojvodic D, Baletic N, Zaletel I, Stanojevic I, et al. Serum cytokine profile of laryngeal squamous cell carcinoma patients. J Laryngol Otol. 2017 May;131(5):455-61.
29. Chuerduangphui J, Pientong C, Chaiyarit P, Patarapadungkit N, Chotiyano A, Kongyingyoes B, et al. Effect of human papillomavirus 16 oncoproteins on oncostatin M upregulation in oral squamous cell carcinoma. Med Oncol. 2016 Aug;33(8):83.
30. Guerrera IC, Quetier I, Fetouchi R, Moreau F, Vauloup-Fellous C, Lekbaby B, et al. Regulation of interleukin-6 in head and neck squamous cell carcinoma is related to papillomavirus infection. J Proteome Res. 2014 Feb;13(2):1002-11.
31. Allen C, Duffy S, Teknos T, Islam M, Chen Z, Albert PS, et al. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res. 2007 Jun;13(11):3182-90.
32. Hao W, Zhu Y, Zhou H. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol. 2013 Mar;30(1):333.
34. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008 Aug;113(4):750-7.
35. Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD, et al. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys. 2010 Mar;76(4):1214-24.
36. Shinagawa K, Yanamoto S, Naruse T, Kawakita A, Morishita K, Sakamoto Y, et al. Clinical roles of interleukin-6 and STAT3 in oral squamous cell carcinoma. Pathol Oncol Res. 2017 Apr;23(2):425-31.
39. Lesinski GB, Nannapaneni S, Griffith CC, Patel M, Chen W, Chen Z, et al. Interleukin-6/STAT3 signaling is prominent and associated with reduced overall survival in p16 negative oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2019 Sep;13(3):304-12.
46. SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A. Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2008 May;13(5):E292-5.
47. Sato J, Goto J, Murata T, Kitamori S, Yamazaki Y, Satoh A, et al. Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Sep;110(3):330-6.
48. Vucicevic Boras V, Cikes N, Lukac J, Virag M, Cekic-Arambasin A. Salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with oral squamous cell carcinoma. Minerva Stomatol. 2005 Oct;54(10):569-73.
49. Katakura A, Kamiyama I, Takano N, Shibahara T, Muramatsu T, Ishihara K, et al. Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll. 2007 Nov;48(4):199-203.
50. Hamad AW, Gaphor SM, Shawagfeh MT, Al-Talabani NG. Study of serum and salivary levels of proinflammatory cytokines, potential biomarkers in the diagnosis of oral squamous cell carcinoma. Acad J Cancer. 2011;4(2):47-55.
51. Panneer Selvam N, Sadaksharam J. Salivary interleukin-6 in the detection of oral cancer and precancer. Asia Pac J Clin Oncol. 2015 Sep;11(3):236-41.
53. Juretic M, Cerovic R, Belusic-Gobic M, Brekalo Prso I, Kqiku L, Spalj S, et al. Salivary levels of TNF-α and IL-6 in patients with oral premalignant and malignant lesions. Folia Biol (Praha). 2013;59(2):99-102.
54. Lisa Cheng YS, Jordan L, Gorugantula LM, Schneiderman E, Chen HS, Rees T. Salivary interleukin-6 and -8 in patients with oral cancer and patients with chronic oral inflammatory diseases. J Periodontol. 2014 Jul;85(7):956-65.
55. Korostoff A, Reder L, Masood R, Sinha UK. The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol. 2011 Apr;47(4):282-7.
57. Sato J, Ohuchi M, Abe K, Satoh T, Abe T, Yamazaki Y, et al. Correlation between salivary interleukin-6 levels and early locoregional recurrence in patients with oral squamous cell carcinoma: preliminary study. Head Neck. 2013 Jun;35(6):889-94.
58. Sato J, Ohuchi M, Wada M, Ohga N, Asaka T, Yoshikawa K, et al. Differences in sequential posttreatment salivary IL-6 levels between patients with and patients without locoregional recurrences of oral squamous cell carcinoma: part III of a cohort study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Dec;120(6):751-60.
59. Arduino PG, Menegatti E, Cappello N, Martina E, Gardino N, Tanteri C, et al. Possible role for interleukins as biomarkers for mortality and recurrence in oral cancer. Int J Biol Markers. 2015 May;30(2):e262-6.
60. Bossi P, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C, et al. Salivary cytokine levels and oral mucositis in head and neck cancer patients treated with chemotherapy and radiation therapy. Int J Radiat Oncol Biol Phys. 2016 Dec;96(5):959-66.
61. Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, et al. Cancer cachexia update in head and neck cancer: definitions and diagnostic features. Head Neck. 2015 Apr;37(4):594-604.
62. Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, et al. Cancer cachexia update in head and neck cancer: pathophysiology and treatment. Head Neck. 2015 Jul;37(7):1057-72.
63. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012 Aug;16(2):153-66.
64. Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care. 2014 Dec;8(4):321-7.
67. Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology. 1991 May;128(5):2657-9.
69. Richey LM, George JR, Couch ME, Kanapkey BK, Yin X, Cannon T, et al. Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res. 2007 Nov;13(22 Pt 1):6561-7.
70. de Carvalho TM, Miguel Marin D, da Silva CA, de Souza AL, Talamoni M, Lima CS, et al. Evaluation of patients with head and neck cancer performing standard treatment in relation to body composition, resting metabolic rate, and inflammatory cytokines. Head Neck. 2015 Jan;37(1):97-102.
72. Kamperos G, Nikitakis N, Sfakianou A, Avgoustidis D, SklavounouAndrikopoulou A. Expression of NF-κB and IL-6 in oral precancerous and cancerous lesions: an immunohistochemical study. Med Oral Patol Oral Cir Bucal. 2016 Jan;21(1):e6-13.
73. Hsu HJ, Yang YH, Shieh TY, Chen CH, Kao YH, Yang CF, et al. Role of cytokine gene (interferon-γ, transforming growth factor-β1, tumor necrosis factor-α, interleukin-6, and interleukin-10) polymorphisms in the risk of oral precancerous lesions in Taiwanese. Kaohsiung J Med Sci. 2014 Nov;30(11):551-8.
74. Gaur P, Mittal M, Mohanti B, Das S. Functional variants of IL4 and IL6 genes and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Oral Dis. 2011 Oct;17(7):720-6.
75. Lopez RV, Zago MA, Eluf-Neto J, Curado MP, Daudt AW, da SilvaJunior WA, et al. Education, tobacco smoking, alcohol consumption, and IL-2 and IL-6 gene polymorphisms in the survival of head and neck cancer. Braz J Med Biol Res. 2011 Oct;44(10):1006-12.
78. Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005 Oct;44(2):77-82.
79. Bran G, Gotte K, Riedel K, Hormann K, Riedel F. IL-6 antisensemediated growth inhibition in a head and neck squamous cell carcinoma cell line. In Vivo. 2011 Jul-Aug;25(4):579-84.
80. Kayamori K, Sakamoto K, Nakashima T, Takayanagi H, Morita K, Omura K, et al. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol. 2010 Feb;176(2):968-80.
81. Bolt R, Foran B, Murdoch C, Lambert DW, Thomas S, Hunter KD. HPV-negative, but not HPV-positive, oropharyngeal carcinomas induce fibroblasts to support tumour invasion through micro-environmental release of HGF and IL-6. Carcinogenesis. 2018 Feb;39(2):170-9.
82. Schiegnitz E, Kammerer PW, Schon H, Blatt S, Berres M, Sagheb K, et al. Proinflammatory cytokines as serum biomarker in oral carcinoma-A prospective multi-biomarker approach. J Oral Pathol Med. 2018 Mar;47(3):268-74.
83. Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2004 Nov;131(5):573-6.
84. Li C, Zhao Y, Zhang W, Zhang W. Increased prevalence of T(H)17 cells in the peripheral blood of patients with head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Jul;112(1):81-9.
85. Mojtahedi Z, Khademi B, Hashemi SB, Abtahi SM, Ghasemi MA, Fattahi MJ, et al. Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res. 2011 Mar;17(1):7-10.
86. Chang PY, Kuo YB, Wu TL, Liao CT, Sun YC, Yen TC, et al. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer. Clin Chem Lab Med. 2013 Jun;51(6):1291-300.
88. Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, et al. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Oncogene. 2018 Jan;37(3):377-88.
91. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer. 2006 Sep;119(6):1268-75.
92. Cohen AN, Veena MS, Srivatsan ES, Wang MB. Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch Otolaryngol Head Neck Surg. 2009 Feb;135(2):190-7.
93. Meyer C, Pries R, Wollenberg B. Established and novel NF-κB inhibitors lead to downregulation of TLR3 and the proliferation and cytokine secretion in HNSCC. Oral Oncol. 2011 Sep;47(9):818-26.
94. Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res. 2013 Jun;73(11):3425-40.
95. Lin HY, Hou SC, Chen SC, Kao MC, Yu CC, Funayama S, et al. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells. J Agric Food Chem. 2012 Mar;60(10):2480-9.
96. Macha MA, Matta A, Chauhan SS, Siu KW, Ralhan R. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells. Carcinogenesis. 2011 Mar;32(3):368-80.
97. Tamatani T, Azuma M, Motegi K, Takamaru N, Kawashima Y, Bando T. Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells. Int J Oncol. 2007 Oct;31(4):761-8.
98. Tu DG, Lin WT, Yu CC, Lee SS, Peng CY, Lin T, et al. Chemotherapeutic effects of luteolin on radio-sensitivity enhancement and interleukin-6/signal transducer and activator of transcription 3 signaling repression of oral cancer stem cells. J Formos Med Assoc. 2016 Dec;115(12):1032-8.
100. Wichmann G, Cedra S, Schlegel D, Kolb M, Wiegand S, Boehm A, et al. Cilengitide and cetuximab reduce cytokine production and colony formation of head and neck squamous cell carcinoma cells ex vivo. Anticancer Res. 2017 Feb;37(2):521-7.
101. Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, et al. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Clin Cancer Res. 2005 Apr;11(7):2713-9.
102. DiNatale BC, Schroeder JC, Perdew GH. Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines. Mol Carcinog. 2011 Mar;50(3):173-83.
104. Ekshyyan O, Khandelwal AR, Rong X, Moore-Medlin T, Ma X, Alexander JS, et al. Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells. Am J Transl Res. 2016 Nov;8(11):4822-30.
106. Hwang YS, Ahn SY, Moon S, Zheng Z, Cha IH, Kim J, et al. Insulinlike growth factor-II mRNA binding protein-3 and podoplanin expression are associated with bone invasion and prognosis in oral squamous cell carcinoma. Arch Oral Biol. 2016 Sep;69:25-32.
108. Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep;15(17):5426-34.
109. Shinriki S, Jono H, Ueda M, Ota K, Ota T, Sueyoshi T, et al. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol. 2011 Sep;225(1):142-50.
112. Poth KJ, Guminski AD, Thomas GP, Leo PJ, Jabbar IA, Saunders NA. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma. Mol Cancer Ther. 2010 Aug;9(8):2430-9.
113. Ruan M, Thorn K, Liu S, Li S, Yang W, Zhang C, et al. The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma. Int J Oncol. 2014 Jun;44(6):2103-10.
116. Riebe C, Pries R, Kemkers A, Wollenberg B. Increased cytokine secretion in head and neck cancer upon p38 mitogen-activated protein kinase activation. Int J Mol Med. 2007 Dec;20(6):883-7.
118. Kross KW, Heimdal JH, Olsnes C, Olofson J, Aarstad HJ. Tumourassociated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue. Acta Otolaryngol. 2007 May;127(5):532-9.
121. Teknos TN, Islam M, Arenberg DA, Pan Q, Carskadon SL, Abarbanell AM, et al. The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2005 Mar;131(3):204-11.
124. Zhou X, Ren Y, Liu A, Han L, Zhang K, Li S, et al. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep. 2014 May;31(5):2173-80.
125. Chang MT, Lee SP, Fang CY, Hsieh PL, Liao YW, Lu MY, et al. Chemosensitizing effect of honokiol in oral carcinoma stem cells via regulation of IL-6/Stat3 signaling. Environ Toxicol. 2018 Nov;33(11):1105-12.
126. Wang TH, Fang JY, Wu SJ, Liu YW, Chan CW, Chuang SY, et al. 2-O-methylmagnolol induces apoptosis and inhibits IL-6/STAT3 signaling in oral squamous cell carcinoma. Cell Physiol Biochem. 2018;50(3):883-92.